Natera, Inc. $100 Million Follow-On Public Offering
Davis Polk advised the several underwriters in connection with the follow-on offering of 5,263,158 shares of common stock of Natera, Inc. for total gross proceeds of approximately $100…
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Alector, Inc. Initial Public Offering
Davis Polk advised the underwriters in connection with an initial public offering of 9,250,000 shares of common stock of Alector, Inc. at $19.00 per share, for total gross proceeds of $175…
Secondary Offering of NeoGenomics, Inc. Common Stock
Davis Polk advised the sole book-runner in connection with the SEC-registered secondary offering of 10,835,145 shares of common stock of NeoGenomics, Inc. by the selling stockholder, GE…
Kala Pharmaceuticals, Inc. Common Stock Offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the SEC-registered offering of 7,500,000 shares of common stock of…
NeoGenomics Follow-On Offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the approximately $125 million public offering of common stock of…
Natera, Inc. $103.5 Million Follow-On Public Offering
Davis Polk advised the representatives of the underwriters in connection with the follow-on offering of 5,175,000 shares of common stock for Natera, Inc. for total gross proceeds of …
Ardelyx, Inc. $50 Million Public Offering
Davis Polk advised the joint book-running managers for a $50 million public offering of common stock by Ardelyx, Inc. The common stock is listed on the NASDAQ Global Market under the…
Coherus BioSciences, Inc. $86.25 Million Follow-On Offering
Davis Polk advised the joint book-running managers in connection with the $86.25 million public offering of common stock of Coherus BioSciences, Inc.
Based in Redwood City, California,…
Shire $2.4 billion sale of its Oncology business to Servier
Davis Polk is advising Shire plc on the $2.4 billion sale of its Oncology business to Servier S.A.S. The transaction has been approved by the board of directors and is expected to close in…
Davis Polk Advises Charles River Laboratories International, Inc. on Its $500 Million Notes Offering
Davis Polk advised Charles River Laboratories International, Inc. in connection with its Rule 144A/Regulation S offering of $500 million aggregate principal amount of 5.500% senior notes…